Difficulty: Medium
Average Score: 69%
Practice
Children with high-risk neuroblastoma have poor survival. Current treatment consists of all the following EXCEPT
Correct answer
E
Rationale
In the context of pediatric oncology, high-risk neuroblastoma is an aggressive form of cancer with poor survival rates. The current treatment modalities for this condition aim to aggressively target and eradicate the cancer cells.
The correct answer, option E (immunotherapy), is an essential component of the treatment regimen for high-risk neuroblastoma. Immunotherapy uses the body's immune system to help fight cancer and has shown promising results in improving survival rates in children with this condition.
Option A, surgery, is often used to remove the primary tumor in neuroblastoma. However, neuroblastoma is known for its high recurrence rates even after surgery, hence surgery alone is not sufficient for treatment.
Option B, intensive chemotherapy, is a standard treatment for high-risk neuroblastoma to kill cancer cells. Chemotherapy is typically used in combination with other modalities for a more comprehensive approach.
Option C, radiation therapy, may be used in neuroblastoma treatment to target and shrink tumors. However, it is often avoided in young children due to potential long-term side effects on developing organs.
Option D, allogeneic bone marrow transplantation, is not a standard treatment for high-risk neuroblastoma. While it may be considered in certain cases, it is not a primary treatment modality for this condition.
In an educational context, understanding the rationale behind each treatment option is crucial for nurses caring for pediatric oncology patients. It helps them comprehend the holistic approach to managing high-risk neuroblastoma and the importance of multidisciplinary collaboration in providing optimal care for these vulnerable patients.
The correct answer, option E (immunotherapy), is an essential component of the treatment regimen for high-risk neuroblastoma. Immunotherapy uses the body's immune system to help fight cancer and has shown promising results in improving survival rates in children with this condition.
Option A, surgery, is often used to remove the primary tumor in neuroblastoma. However, neuroblastoma is known for its high recurrence rates even after surgery, hence surgery alone is not sufficient for treatment.
Option B, intensive chemotherapy, is a standard treatment for high-risk neuroblastoma to kill cancer cells. Chemotherapy is typically used in combination with other modalities for a more comprehensive approach.
Option C, radiation therapy, may be used in neuroblastoma treatment to target and shrink tumors. However, it is often avoided in young children due to potential long-term side effects on developing organs.
Option D, allogeneic bone marrow transplantation, is not a standard treatment for high-risk neuroblastoma. While it may be considered in certain cases, it is not a primary treatment modality for this condition.
In an educational context, understanding the rationale behind each treatment option is crucial for nurses caring for pediatric oncology patients. It helps them comprehend the holistic approach to managing high-risk neuroblastoma and the importance of multidisciplinary collaboration in providing optimal care for these vulnerable patients.